Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19 - Moderna Investor Relations
CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA…